Postmarket policy considerations for biosimilar oncology drugs

The Lancet Oncology

Volumn 17, Issue 1, 2016, Pages e31-e38

  Renwick, Matthew J ^a   Smolina, Kate ^a   Gladstone, Emilie J ^a   Weymann, Deirdre ^a   Morgan, Steven G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOSIMILAR AGENT; FILGRASTIM; INFLIXIMAB;

BELGIUM; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG COST; DRUG DESIGN; DRUG MARKETING; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; FRANCE; GERMANY; HOSPITAL FINANCE; HUMAN; ITALY; LICENSING; NETHERLANDS; NORWAY; POLICY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM; UNITED STATES; CLINICAL PRACTICE; DRUG LEGISLATION; DRUG UTILIZATION; ECONOMIC ASPECT; ECONOMICS; EUROPE; HEALTH CARE POLICY; LEGISLATION AND JURISPRUDENCE; PHARMACY; STATISTICS AND NUMERICAL DATA;

ANTINEOPLASTIC AGENTS; BIOSIMILAR PHARMACEUTICALS; DRUG COSTS; DRUG SUBSTITUTION; DRUG UTILIZATION; ECONOMIC COMPETITION; EUROPE; HEALTH POLICY; HUMANS; LEGISLATION, DRUG; PHARMACIES; PRACTICE PATTERNS, PHYSICIANS'; UNITED STATES;

EID: 84955255418     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00381-2     Document Type: Review

References (67)

1. Calo-Fernández B, Martínez-Hurtado JL Biosimilars: company strategies to capture value from the biologics market. Pharmaceuticals (Basel) 2012, 5:1393-1408.
2. Strand V, Cronstein B Biosimilars: how similar?. Intern Med J 2014, 44:218-223.
3. Garber AJ Biosimilar products are not bioidentical. J Diabetes 2015, 7:153-154.
4. Kanase SJ, Gavhane YN, Khandekar A, Gurav AS, Yadav AV Biosimilar: an overview. Int J Pharm Sci Rev Res 2013, 4:2132.
5. Rak Tkaczuk KH, Jacobs IA Biosimilars in oncology: from development to clinical practice. Semin Oncol 2014, 41(suppl 3):S3-12.
6. Malik NN Controlling the cost of innovative cancer therapeutics. Nat Rev Clin Oncol 2009, 6:550-552.
7. Cornes P The economic pressures for biosimilar drug use in cancer medicine. Target Oncol 2012, 7(suppl 1):S57-S67.
8. Nowicki M Basic facts about biosimilars. Kidney Blood Press Res 2007, 30:267-272.
9. Bennett CL, Chen B, Hermanson T, et al. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol 2014, 15:e594-e605.
10. Morgan S, Kennedy J, Boothe K, McMahon M, Watson D, Roughead E Toward an understanding of high performance pharmaceutical policy systems: a "Triple-A" framework and example analysis. Open Health Serv Policy J 2009, 2:1-9.
11. Roger SD Biosimilars: current status and future directions. Expert Opin Biol Ther 2010, 10:1011-1018.
12. European public assessment reports: authorized biosimilars European Medicines Agency, (accessed Aug 27, 2015). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125.
13. Assessing biosimilar uptake and competition in European markets IMS Institute for Healthcare Informatics, (accessed March 25, 2015). http://www.imshealth.com/imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Insights/Assessing_biosimilar_uptake_and_competition_in_European_markets.pdf.
14. Rovira J, Espin J, Garcia L, de Labry AO The impact of biosimilars' entry in the EU market. Andalusian School of Public Health (accessed March 25, 2015). http://ec.europa.eu/DocsRoom/documents/7651/attachments/1/translations/en/renditions/pdf.
15. Koutnik-Fotopoulos E Tbo-filgrastim shows significant cost savings for payers. First Rep Managed Care 2014, 11.
16. Senior M First US biosimilar edges towards market. Nat Biotechnol 2015, 33:222-223.
17. FDA approves first biosimilar Zarxio US Food and Drug Administration, (accessed April 15, 2015). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm.
18. Amgen, Inc. vs Sandoz, Inc., No. 15-1499 US Court of Appeals for the Federal Circuit, (accessed Aug 28, 2015). http://law.justia.com/cases/federal/appellate-courts/cafc/15-1499/15-1499-2015-07-21.html.
19. Requests that the FDA adopt policies and practices in their acceptance and review of biosimilar applications that will provide for the orderly implementation and efficient functioning of the BPCIA. The Office of the Federal Register US Food and Drug Administration, (accessed Aug 27, 2015). http://www.regulations.gov/#!docketDetail;D=FDA-2014-P-1771.
20. Ebbers HC, Crow SA, Vulto AG, Schellekens H Interchangeability, immunogenicity and biosimilars. Nat Biotechnol 2012, 30:1186-1190.
21. Ebbers HC, Muenzberg M, Schellekens H The safety of switching between therapeutic proteins. Expert Opin Biol Ther 2012, 12:1473-1485.
22. Tóthfalusi L, Endrényi L, Chow SC Statistical and regulatory considerations in assessments of interchangeability of biological drug products. Eur J Health Econ 2014, 15(suppl 1):S5-11.
23. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004, 351:1403-1408.
24. Ventola CL Biosimilars: part 1: proposed regulatory criteria for FDA approval. P T 2013, 38:270-287.
25. EMA procedural advice for users of the Centralised Procedure for Similar Medicinal Products applications European Medicines Agency, (accessed July 23, 2015). http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/WC500125166.pdf.
26. Zelenetz AD, Ahmed I, Braud EL, et al. NCCN biosimilars white paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw 2011, 9(suppl 4):S1-22.
27. Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin 2008, 24:625-637. the Epoetin Zeta Study Group.
28. Cho SH, Lim HS, Ghim JL, et al. Pharmacokinetic, tolerability, and bioequivalence comparison of three different intravenous formulations of recombinant human erythropoietin in healthy Korean adult male volunteers: an open-label, randomized-sequence, three-treatment, three-way crossover study. Clin Ther 2009, 31:1046-1053.
29. Grabowski HG, Ridley DB, Schulman KA Entry and competition in generic biologics. Manage Decis Econ 2007, 28:439-451.
30. Chauhan D, Towse A, Mestre-Ferrandiz J The market for biosimilars: evolution and policy options. Office of Health Economics (accessed July 23, 2015). https://www.ohe.org/publications/market-biosimilars-evolution-and-policy-options.
31. Schellekens H Biosimilar therapeutics-what do we need to consider?. NDT Plus 2009, 2(suppl 1):i27-i36.
32. Kvien TK Remsima in Norway and Europe. 16th APLAR Congress. Oslo, Norway. April 2-4 2014 (accessed July 23, 2015). http://aplarcongress.org/wp-content/uploads/2014/04/1.-Prof.-Tore-Kvien_welcome-message.pdf.
33. Vulto AG, Crow SA Risk management of biosimilars in oncology: each medicine is a work in progress. Target Oncol 2012, 7(suppl 1):S43-S49.
34. Frau S, Font Pous M, Luppino MR, Conforti A Risk management plans: are they a tool for improving drug safety?. Eur J Clin Pharmacol 2010, 66:785-790.
35. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 2008, 300:1887-1896.
36. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, et al. Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval. Drug Saf 2009, 32:1175-1187.
37. Lepage-Nefkens I, Gerkens S, Vinck I, Pierart J, Hulstaert F, Farfan-Portet M-I Chapter 6: International comparison of policies stimulating biosimilar uptake. Barriers and opportunities for the uptake of biosimilar medicines in Belgium. Belgian Health Care Knowledge Centre (accessed May 5, 2015). https://www.kce.fgov.be/sites/default/files/page_documents/KCE_199_2012-13-HSR_Biosimilars_report_0.pdf.
38. Lepage-Nefkens I, Gerkens S, Vinck I, Pierart J, Hulstaert F, Farfan-Portet M-I Chapter 4: Biosimilars in the Belgian context. Barriers and opportunities for the uptake of biosimilar medicines in Belgium. Belgian Health Care Knowledge Centre (accessed May 5, 2015). https://www.kce.fgov.be/sites/default/files/page_documents/KCE_199_2012-13-HSR_Biosimilars_report_0.pdf.
39. Liefner M Biosimilars: Price dynamics in Europe. Biosimilars: How much entry and price competition will result? 2010, Office of Health Economics, London. N. Mattison, J. Mestre-Ferrandiz, A. Towse (Eds.).
40. Dolinar RO, Reilly MS Biosimilars naming, label transparency, and authority of choice: survey findings among European physicians. GaBI J 2014, 3:58-62.
41. Kanavos P, Costa-Font J, Seeley E Competition in off-patent drug markets: issues, regulation and evidence 2009, 501-545. Blackwell Publishing Ltd, Economic Policy, Hoboken.
42. 2014 Social Security and Finance Bill Conseil Constitutionnel. Décision no. 2013-682 (accessed Aug 27, 2015). http://www.conseil-constitutionnel.fr/decision/2013/2013%E2%80%93682-dc/decision-n-2013%E2%80%93682-dc-du-19-december-2013.138972.html.
43. MEB position on prescription of "biosimilar medicinal products" Dutch Medicines Evaluation Board, (accessed May 25, 2015). http://www.cbg-meb.nl/CBG/en/human-medicines/actueel/150331_MEB_position_on_prescription_of_biosimilar_medicinal_products/default.htm.
44. Dylst P, Vulto A, Simoens S How can pharmacist remuneration systems in Europe contribute to generic medicine dispensing?. Pharm Pract (Granada) 2012, 10:3-8.
45. Causey LL Nuts and bolts of pharmacy reimbursement: why it should matter to you. University of Houston Health Law Perspectives (accessed July 7, 2015). https://www.law.uh.edu/healthlaw/perspectives/2009/(LC)%20Pharmacy.pdf.
46. Food and Drug Administration approval of first biosimilar product US Centers for Medicare and Medicaid Services, (accessed July 29, 2015). http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/SE1509.pdf.
47. What pricing and reimbursement policies to use for off-patent biologicals? Results from the EBE 2014 biological medicines policy survey. GaBI J 2015, 4:17-24. European Biopharmaceuticals Enterprise.
48. International trends series part 4: uptake of biosimilars PDCI Market Access, (accessed Aug 27, 2015). http://www.pdci.ca/2015/05/26/pdci-international-trends-series-part-4.
49. Dylst P, Vulto A, Simoens S Barriers to the uptake of biosimilars and possible solutions: a Belgian case study. Pharmacoeconomics 2014, 32:681-691.
50. Curto A, Van de Vooren K, Garattini L, Lo Muto R, Duranti S Regional tenders on biosimilars in Italy: potentially competitive?. GaBI J 2013, 2:123-129.
51. Simoens S, Verbeken G, Huys I Biosimilars and market access: a question of comparability and costs?. Target Oncol 2012, 7:227-231.
52. Grabowski H, Cockburn I, Long G The market for follow-on biologics: how will it evolve?. Health Aff (Millwood) 2006, 25:1291-1301.
53. Guidelines for price setting in Norway Norwegian Medicines Agency, (accessed April 23, 2015). http://www.legemiddelverket.no/English/price:and_reimbursement/maximum-price/Documents/Guidelines%20for%20price%20setting%20in%20Norway%20oppdatert.docx.
54. AIFA position paper: i farmaci biosimilari Agenzia Italiana del Farmaco, (accessed Aug 27, 2015). http://www.agenziafarmaco.gov.it/sites/default/files/AIFA_POSITION_PAPER_FARMACI_BIOSIMILARI.pdf.
55. Drummond M, Jönsson B, Rutten F, Stargardt T Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. Eur J Health Econ 2011, 12:263-271.
56. The Pharmaceutical Price and Regulation Scheme 2014 2013, Finance and NHS/Medicines, Pharmacy and Industry Group/17080Pharmacy and Industry Group/17080, UK Department of Health, London.
57. Understanding the 2014 Pharmaceutical Price Regulation Scheme Association of the British Pharmaceutical Industry, (accessed July 23, 2015). http://www.abpi.org.uk/our-work/policy-parliamentary/Documents/understanding_pprs2014.pdf.
58. World Preview 2014, Outlook to 2020 EvaluatePharma, (accessed July 5, 2015). http://info.evaluategroup.com/rs/evaluatepharmaltd/images/EP240614.pdf.
59. Abraham J Developing oncology biosimilars: an essential approach for the future. Semin Oncol 2013, 40(suppl 1):S5-24.
60. Kozlowski S, Woodcock J, Midthun K, Sherman RB Developing the nation's biosimilars program. N Engl J Med 2011, 365:385-388.
61. Guidelines on evaluation of similar biotherapeutic products (SBPs) 2009, Expert committee on biological standardization, World Health Organization, Geneva, (accessed June 23, 2015).
62. Gal A Biosimilars: commercial perspective. Follow-on biologics workshop: impact of recent legislative and regulatory naming proposals; February 4 2014; Washington, DC: Sanford C. Bernstein & Co. (accessed June 15, 2015). https://www.ftc.gov/system/files/documents/public_events/Follow-On%20Biologics%20Workshop%3A%20Impact%20of%20Recent%20Legislative%20and%20Regulatory%20Naming%20Proposals%20on%20Competition/gal.pdf.
63. Farfan-Portet M-I, Gerkens S, Lepage-Nefkens I, Vinck I, Hulstaert F Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?. Eur J Health Econ 2014, 15:223-228.
64. Biopharmaceutical industry pipeline for SEBs. In: Subsequent entry biologics: emerging trends in regulatory and health technology assessment Canadian Agency for Drugs and Technologies in Health, (accessed Feb 18, 2015). http://www.cadth.ca/products/environmental-scanning/environmental-scans/environmental-scan-43.
65. Kim Y, Choi B, Yang S, et al. Biosimilars: challenges and path forward. Biotechnol Bioprocess Eng 2014, 19:755-765.
66. Thill M New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer. Expert Rev Anticancer Ther 2015, 15:331-338.
67. Scott BJ, Klein AV, Wang J Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation. J Clin Pharmacol 2015, 55(suppl 3):S123-S132.